Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells

Biomaterials

Volumn 34, Issue 19, 2013, Pages 4655-4666

  Medina, Scott H ^a   Chevliakov, Maxim V ^a   Tiruchinapally, Gopinath ^a   Durmaz, Yasemin Yuksel ^a   Kuruvilla, Sibu P ^a   ElSayed, Mohamed E H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Azo linkers; Azoreductase enzymes; Enzyme sensitive linkers; Hepatic cancer; PAMAM dendrimers; Polymer anticancer drug conjugates

Indexed keywords

AZO-LINKERS; AZOREDUCTASE; DRUG-CONJUGATES; ENZYME-SENSITIVE LINKERS; HEPATIC CANCER; PAMAM DENDRIMER;

CELLS; CHEMICAL BONDS; CYTOLOGY; CYTOTOXICITY; DENDRIMERS; ELECTRONEGATIVITY; ENZYMES; MOLECULES; ORGANIC POLYMERS;

NANOCONJUGATES;

AROMATIC COMPOUND; AZO REDUCTASE; DENDRIMER; DOXORUBICIN; ENZYME; HUMAN LIVER MICROSOMAL ENZYME; NANOCONJUGATE; NITROGEN; OXYGEN; POLYAMIDOAMINE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ISOLATION; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTRON; ENZYME BINDING; ENZYME SYNTHESIS; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; LIVER CANCER; LIVER MICROSOME; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DENDRIMERS; DOXORUBICIN; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; MYOCYTES, CARDIAC; NANOCONJUGATES; POLYAMINES; RATS;

HEXAPODA; RATTUS;

EID: 84875840121     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.070     Document Type: Article

References (58)

1. ACS. editor. Atlanta: American Cancer Society; 2011.
2. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
3. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
4. Poon R.T.-P., Fan S.-T.F., Tsang F.H.-F., Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002, 235:466-486.
5. Yamada R., Kishi K., Sato M., Sonomura T., Nishida N., Tanaka K., et al. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg 1995, 19:795-800.
6. Skitzki J.J., Chang A.E. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol 2002, 11:123-135.
7. Li L., Tang F., Liu H., Liu T., Hao N., Chen D., et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4:6874-6882.
8. Liu S.-Y., Liang Z.-S., Gao F., Luo S.-F., Lu G.-Q. In vitro photothermal study of gold nanoshells functionalized with small targeting peptides to liver cancer cells. J Mater Sci Mater Med 2010, 21:665-674.
9. Maeng J.H., Lee D.-H., Jung K.H., Bae Y.-H., Park I.-S., Jeong S., et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010, 31:4995-5006.
10. Na K., Park K.-H., Kim S.W., Bae Y.H. Self-assembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2). J Control Release 2000, 69:225-236.
11. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001, 46:169-185.
12. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., et al. Preclinical evaluation of polymer-bound doxorubicin. J Control Release 1992, 19:331-346.
13. Kopeček J., Kopečková P., Minko T., Lu Z.-R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000, 50:61-81.
14. David A., Kopečková P., Rubinstein A., Kopeček J. Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem 2001, 12:890-899.
15. Tang A., Kopečková P., Kopeček J. Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes. Pharm Res 2003, 20:360-367.
16. Lammers T., Kühnlein R., Kissel M., Subr V., Etrych T., Pola R., et al. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release 2005, 110:103-118.
17. Gao S.-Q., Lu Z.-R., Petri B., Kopečková P., Kopeček J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release 2006, 110:323-331.
18. Zbaida S. Nitroreductases and azoreductases. Enzyme systems that metabolise drugs and other xenobiotics 2002, John Wiley & Sons, Ltd., p. 555-66.
19. Zbaida S., Brewer C.F., Levine W.G. Substrates for microsomal azoreductase. Hammett substituent effects, NMR studies, and response to inhibitors. Drug Metab Dispos 1992, 20:902-908.
20. Zbaida S., Brewer C.F., Levine W.G. Hepatic microsomal azoreductase activity. Reactivity of azo dye substrates is determined by their electron densities and redox potentials. Drug Metab Dispos 1994, 22:412-418.
21. de Groot F.M.H., Loos W.J., Koekkoek R., van Berkom L.W.A., Busscher G.F., Seelen A.E., et al. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J Org Chem 2001, 66:8815-8830.
22. Hammett L.P. The effect of structure upon the reactions of organic compounds. Benzene derivatives. J Am Chem Soc 1937, 59:96-103.
23. McDaniel D.H., Brown H.C. An extended table of Hammett substituent constants based on the ionization of substituted benzoic acids. J Org Chem 1958, 23:420-427.
24. Franken N.A.P., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006, 1:2315-2319.
25. Westfall M.V., Rust E.M., Albayya F., Metzger J.M. Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods in cell biology 1997, 307-322. Academic Press. P.E. Charles, H.L. Sweeney (Eds.).
26. Wahr P.A., Michele D.E., Metzger J.M. Effects of aging on single cardiac myocyte function in Fischer 344 × Brown Norway rats. Am J Physiol Heart Circ Physiol 2000, 279:H559-H565.
27. van de Kerkhof E.G., de Graaf I.A., Groothuis G.M.M. In vitro methods to study intestinal drug metabolism. Curr Drug Metab 2007, 8:658-675.
28. Medina S.H., Tekumalla V., Chevliakov M.V., Shewach D.S., Ensminger W.D., El-Sayed M.E.H. N-Acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 2011, 32:4118-4129.
29. Kim J.-H., El-Khouly M.E., Araki Y., Ito O., Kay K.-Y. Photoinduced processes of subphthalocyanine-diazobenzene-fullerene triad as an efficient excited energy transfer system. Chem Lett 2008, 37:544-545.
30. Yoo H.S., Park T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001, 70:63-70.
31. Ct Ornelas, Broichhagen J., Weck M. Strain-promoted alkyne azide cycloaddition for the functionalization of poly(amide)-based dendrons and dendrimers. J Am Chem Soc 2010, 132:3923-3931.
32. Zbaida S., Levine W.G. A novel application of cyclic voltammetry for direct investigation of metabolic intermediates in microsomal azo reduction. Chem Res Toxicol 1991, 4:82-88.
33. Sadekar S., Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 2012, 64:571-588.
34. Greish K., Thiagarajan G., Herd H., Price R., Bauer H., Hubbard D., et al. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 2011, 6:713-723.
35. Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
36. Aubel-Sadron G., Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984, 66:333-352.
37. Luo Y., Bernshaw N.J., Lu Z.-R., Kopecek J., Prestwich G.D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res 2002, 19:396-402.
38. Kono K., Kojima C., Hayashi N., Nishisaka E., Kiura K., Watarai S., et al. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials 2008, 29:1664-1675.
39. Wilkening S., Stahl F., Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 2003, 31:1035-1042.
40. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouët S., Morel F., et al. Expression of cytochromes P450, conjugated enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006, 34:75-83.
41. Wilkening S., Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol 2003, 17:207-213.
42. Fang J., Sawa T., Maeda H. Factors and mechanism of " EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49.
43. Greish K., Fang J., Inutsuka T., Nagamitsu A., Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003, 42:1089-1105.
44. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11:812-818.
45. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul 2001, 41:189-207.
46. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
47. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989, 6:193-210.
48. Medina SH, Tiruchinapally G, Chevliakov MV, Durmaz YY, Stender RN, Ensminger WD, et al. Targeting hepatic cancer cells with PEGylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands. Adv Healthc Mater; accepted.
49. Chandrasekar D., Sistla R., Ahmad F.J., Khar R.K., Diwan P.V. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007, 28:504-512.
50. Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J.W., et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000, 65:133-148.
51. Sadekar S., Ray A., Janaỳt-Amsbury M., Peterson C.M., Ghandehari H. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules 2010, 12:88-96.
52. Gillies E.R., Fréchet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10:35-43.
53. Guo L., Dial S., Shi L., Branham W., Liu J., Fang J.-L., et al. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 2011, 39:528-538.
54. Majer B.J., Mersch-Sundermann V., Darroudi F., Laky B., de Wit K., Knasmüller S. Genotoxic effects of dietary and lifestyle related carcinogens in human derived hepatoma (HepG2, Hep3B) cells. Mutat Res Fundam Mol Mech Mutagen 2004, 551:153-166.
55. Saltiel E., McGuire W. Doxorubicin (adriamycin) cardiomyopathy - a critical review. West J Med 1983, 139:332-341.
56. Chao H.-H., Liu J.-C., Hong H.-J., Lin J.-W., Chen C.-H., Cheng T.-H. L-Carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 2011, 146:145-152.
57. Chiusa M., Hool S.-L., Truetsch P., Djafarzadeh S., Jakob S.M., Seifriz F., et al. Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes. J Mol Cell Cardiol 2012, 52:1164-1175.
58. Anzenbacher P., Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001, 58:737-747.